Abstract: The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.

Abstract: A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.

Abstract: The present invention provides an osmotic dosage form comprising a core containing at least one pharmaceutically active ingredient and which also comprises at least one asymmetric membrane coating wherein said coating comprises one or more substantially water-insoluble polymers, and, one or more solid, water-soluble polymeric materials that do not generate significant amounts of hydrogen peroxide or formaldehyde in long term storage.

Abstract: A controlled release dosage form for sertraline has a core comprising a sertraline-containing composition and a water-swellable composition wherein the water-swellable composition is in a separate region within the core. A coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough. In one embodiment, the dosage form releases sertraline to the use environment at an average rate of 6 to 10 wt % per hour from the second to the twenth hour after introduction to a use environment and less than about 25 wt % for the first two hours and at least 70 wt % by the twelfth hour, where the percentages correspond to the mass of drug released from the tablet divided by the total mass of drug originally present in the tablet.

Abstract: The invention relates to novel pharmaceutical dosage forms of varenicline, which are useful for aiding smoking cessation and which have good storage stability. In particular, the present invention relates to formulations of varenicline wherein the dosage forms that are produced therefrom generate under specified storage conditions less than about 4% on a weight basis of the N-formyl and N-methyl degradation products.

Abstract: The invention provides controlled release pharmaceutical formulations having a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying essentially separate regions within the core. The drug-containing composition comprises a PDE4D inhibitor, or a pharmaceutically acceptable salt thereof, preferably (R)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid, or a pharmaceutically acceptable salt thereof, or 2-(4-fluorophenoxy)-N-[4-(1-hydroxy-1-methyl-ethyl)-benzyl]-nicotinamide, or a pharmaceutically acceptable salt thereof, and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough.

Abstract: An apparatus and method are disclosed herein for processing exposed photosensitive self-developing film in a single use camera.

Abstract: Pharmaceutical kits are provided that reduce or prevent oxidative degradation of oxygen-sensitive pharmaceutically active ingredients in solid unit dosage forms that are supplied in oxygen permeable containers. Stabilization of the active ingredient is accomplished by incorporating an oxygen absorber into a sealed oxygen permeable container.

Abstract: The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.

Abstract: An osmotic pharmaceutical tablet is described which comprises a single-layer compressed core surrounded by a water permeable layer having a passageway. The single-layer core contains (i) a non-ripening drug having a solubility per dose less than about 1 mL−1, (ii) about 2.0% to about 20% by weight of a hydroxyethylcellulose having a weight-average, molecular weight from about 300,000 to about 2,000,000, and (iii) an osmagent.

Abstract: An osmotic pharmaceutical tablet is described which comprises a single-layer compressed core surrounded by a water permeable layer having a passageway. The single-layer core contains (i) a non-ripening drug having a solubility per dose less than about 1 mL−1, (ii) about 2.0% to about 30% by weight of a polyethyleneoxide having a weight-average, molecular weight from about 200,000 to about 7,000,000, (iii) an osmagent, and (iv) an optional disintegrant.

Abstract: A pharmaceutical tablet as well as a process for manufacturing the tablet is described herein. More specifically, a tablet and process of manufacture is described where a drug having a defined rate of delivery is applied by compression onto a compressible coating deposited on a tablet having the same or a different in vivo drug release profile. For the compressible coating, an acrylic acid, methacrylic acid, or ester of either is the preferred monomer for making the polymer in the coating.

Abstract: Pharmaceutical kits are provided that reduce or prevent oxidative degradation of oxygen-sensitive pharmaceutically active ingredients in solid unit dosage forms that are supplied in oxygen permeable containers. Stabilization of the active ingredient is accomplished by incorporating an oxygen absorber into a sealed oxygen permeable container.

Abstract: A pharmaceutical tablet as well as a process for manufacturing the tablet are described herein. More specifically, a tablet and process of manufacture is described where a drug having a defined rate of delivery is applied by compression onto a compressible coating deposited on a tablet having the same or a different in vivo drug release profile.

Abstract: A means for dispensing a single unit dose of an oxygen-sensitive drug without exposing the remaining unit dosages to oxygen is described herein. Each unit dose is individually encapsulated in the pharmaceutical packaging construction such that when one unit dose is dispensed the other unit doses remain encapsulated. An oxygen-absorber is also incorporated into the construction such that the oxygen absorber has sufficient contact with the air surrounding the oxygen-sensitive drug to remove at least a portion of the oxygen in the air to reduce or eliminate undesirable oxidative degradation of the drug in its encapsulated environment.

Abstract: A controlled release dosage form for sertraline has a core comprising a sertraline-containing composition and a water-swellable composition wherein the water-swellable composition is in a separate region within the core. A coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough. In one embodiment, the dosage form releases sertraline to the use environment at an average rate of 6 to 10 wt % per hour from the second to the twenth hour after introduction to a use environment and less than about 25 wt % for the first two hours and at least 70 wt % by the twelfth hour, where the percentages correspond to the mass of drug released from the tablet divided by the total mass of drug originally present in the tablet.

Abstract: There is disclosed an improved photographic apparatus of the self-developing type and method of operation which includes a film assemblage. The camera includes a housing assembly; strip of photographic film; a strip of self-developing photosensitive film; a foldable strip of carrier sheet material; a mechanism for taking up the photosensitive film strip past an exposure station for exposure thereof and for storage of the exposed photosensitive film strip. An advancing mechanism is provided for advancing the exposed photosensitive film strip from the taking up mechanism and the carrier strip through an exit.

Abstract: Certain squaric acid derivatives are useful for the thermochemical generation of acid. The squaric acid derivatives may be used in imaging media in conjunction with acid-sensitive materials which undergo a color change when contacted by the acid generated from the squaric acid derivatives. Preferably, the acid-sensitive materials undergo an irreversible color change, so that the image can be fixed by neutralizing all the acid generated with excess base, thereby preventing further color change in the image during long term storage.

Abstract: An image-receiving element for use in photographic and photothermographic diffusion transfer film units of the type wherein the image-receiving element is designed to be removed or "peeled-apart" from a photosensitive element following exposure and processing. The present image-receiving element comprises in sequence, a support, an image-receiving layer, and an overcoat layer. The overcoat layer comprises a major amount by dry weight of water-insoluble particles and a minor amount by dry weight of a water-insoluble polymeric latex binder material. The water-insoluble particles may comprise inorganic particles such as colloidal silica, and/or organic particles such as water-insoluble polymeric latex particles.

Abstract: There is described a photographic system wherein development of an exposed photosensitive element is carried out in the presence of an acylpyridine-N-oxide compound.